Company profile: Genenta
1.1 - Company Overview
Company description
- Provider of gene transfer therapy for cancer, including Temferon, a lentiviral hematopoietic stem progenitor cell immunotherapy enabling controlled, targeted interferon-α expression within tumors to generate immune responses to TEMs-positive cancers. Offers a proprietary cell-based platform using hematopoietic stem cells to deliver therapeutic payloads in the tumor microenvironment for durable, safe treatment of solid tumors.
Products and services
- Proprietary Platform: Cell-based hematopoietic stem cell system delivering therapeutic payloads within the tumor microenvironment, enabling durable and safe treatments for solid tumors (cell-based)
- Temferon: Lenti-virus based hematopoietic stem progenitor cell immunotherapy enabling controlled, targeted interferon-α expression within cancers, triggering immune responses against TEMs-positive tumors (lenti-virus based)
- Gene Transfer Therapy Development: Gene-transfer-based biotechnology program that develops gene transfer therapy specifically for treating cancer tumors, focusing on tumor-directed therapeutic development (gene-transfer-based)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genenta
Atsena Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies and AAV delivery technologies for inherited retinal diseases: ATSN-101 for GUCY2D-associated LCA1, ATSN-201 leveraging AAV.SPR for XLRS, and ATSN-301 dual AAV vectors for MYO7A-associated USH1B; plus laterally spreading capsids for broad retinal delivery, dual-vector methods for large genes, and intravitreal capsids that evade neutralizing antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atsena Therapeutics company profile →
ReNAgade Therapeutics
HQ: United States
Website
- Description: Provider of RNA therapeutic platforms, offering RNA delivery systems to target previously inaccessible cells, an RNA coding platform (with Orna Therapeutics) for reprogramming cells, proprietary gene editing technology for permanent gene correction, and an all-RNA Gene Therapy 2.0 platform enabling exon and large gene insertions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReNAgade Therapeutics company profile →
Rocket Pharmaceuticals
HQ: United States
Website
- Description: Provider of gene therapies for rare childhood disorders, developing lentiviral and AAV vector-based programs including RP-L102 for Fanconi Anemia, RP-L301 for Pyruvate Kinase Deficiency, an AAV program for Danon Disease, and gene therapies for LAD-I, PKP2 arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rocket Pharmaceuticals company profile →
Foghorn Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foghorn Therapeutics company profile →
Cardior Pharmaceuticals
HQ: Germany
Website
- Description: Provider of non-coding RNA-based therapeutics and related tools for heart disease, including CDR132L (Phase 2) to halt and reverse cardiac remodeling after myocardial infarction; clinical trials in heart failure and MI; the CardiorHealth miR-132 PCR kit to measure circulating miR-132; and an H19 gene therapy approach targeting cardiac hypertrophy and heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardior Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genenta
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genenta
2.2 - Growth funds investing in similar companies to Genenta
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genenta
4.2 - Public trading comparable groups for Genenta
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →